Bishop confirmed as Genesis' executive chair
This article was originally published in Scrip
After joining Genesis Biopharma's board of directors in January (scripintelligence.com, 13 January 2012), Hans Bishop has been made executive chair of the company, which is developing autologous cell therapies for the treatment of cancer. He replaces Anthony Cataldo who will remain on the board as a director. Mr Bishop joined Genesis after having served as chief operating officer of Dendreon.